+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Urinary Tract Infection Market Research Report by Clinical Indication (Cystitis, Pyelonephritis, and Urethritis), Treatment, End User, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 225 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 4986010
UP TO OFF until Mar 31st 2023
The Global Urinary Tract Infection Market size was estimated at USD 10.93 billion in 2022, USD 11.67 billion in 2023, and is projected to grow at a CAGR of 6.91% to reach USD 18.67 billion by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Urinary Tract Infection Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Urinary Tract Infection Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Urinary Tract Infection Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Urinary Tract Infection Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Urinary Tract Infection Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Clinical Indication, the market is studied across Cystitis, Pyelonephritis, and Urethritis.
  • Based on Treatment, the market is studied across Diagnosis and Therapatics. The Therapatics is further studied across Aminoglycosides, Azoles, Quinolones, and β-lactam.
  • Based on End User, the market is studied across Hospitals and Self-Administered.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Connecticut, Florida, Illinois, Maryland, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Texas, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Urinary Tract Infection Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Urinary Tract Infection Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Urinary Tract Infection Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Urinary Tract Infection Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Urinary Tract Infection Market, including AbbVie Inc., Almirall, S.A., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddys Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., Mindray Medical International Limited, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Shionogi & Co., Ltd., Siemens Healthcare AG, Sun Pharmaceutical Industries Limited, Sysmex Corporation, Teva Pharmaceutical Industries Ltd., Urit Medical Electronic Co., Ltd., and Viatris Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Urinary Tract Infection Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Urinary Tract Infection Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Urinary Tract Infection Market?
4. What is the competitive strategic window for opportunities in the Global Urinary Tract Infection Market?
5. What are the technology trends and regulatory frameworks in the Global Urinary Tract Infection Market?
6. What is the market share of the leading vendors in the Global Urinary Tract Infection Market?
7. What modes and strategic moves are considered suitable for entering the Global Urinary Tract Infection Market?
Frequently Asked Questions about the Global Urinary Tract Infection Market

What is the estimated value of the Global Urinary Tract Infection Market?

The Global Urinary Tract Infection Market was estimated to be valued at $10.93 Billion in 2022.

What is the growth rate of the Global Urinary Tract Infection Market?

The growth rate of the Global Urinary Tract Infection Market is 6.9%, with an estimated value of $18.67 Billion by 2030.

What is the forecasted size of the Global Urinary Tract Infection Market?

The Global Urinary Tract Infection Market is estimated to be worth $18.67 Billion by 2030.

Who are the key companies in the Global Urinary Tract Infection Market?

Key companies in the Global Urinary Tract Infection Market include AbbVie Inc., Almirall, S.A., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol, Myers Squibb Company, Cipla Inc. and Eli Lilly and Company.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Diabetes and Kidney Stones
5.1.1.2. High Incidences of UTI in Female Population
5.1.1.3. Complicated UTI due to Rise in Excessive Use of Antibiotics and Drug-Resistance
5.1.2. Restraints
5.1.2.1. Adverse Effects of Urinary Tract Infection Treatment Drugs such as Aminoglycosides and Azoles
5.1.3. Opportunities
5.1.3.1. Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
5.1.3.2. Increase in Awareness among People and Healthcare Expenditure
5.1.4. Challenges
5.1.4.1. Social Stigma Concerning Urinary Tract Infections
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Urinary Tract Infection Market, by Clinical Indication
6.1. Introduction
6.2. Cystitis
6.3. Pyelonephritis
6.4. Urethritis

7. Urinary Tract Infection Market, by Treatment
7.1. Introduction
7.2. Diagnosis
7.3. Therapatics
7.4.1. Aminoglycosides
7.4.2. Azoles
7.4.3. Quinolones
7.4.4. β-lactam

8. Urinary Tract Infection Market, by End User
8.1. Introduction
8.2. Hospitals
8.3. Self-Administered

9. Americas Urinary Tract Infection Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Urinary Tract Infection Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Urinary Tract Infection Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Product Portfolio Analysis, By Key Player
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. AbbVie Inc.
13.2. Almirall, S.A.
13.3. AstraZeneca PLC
13.4. Bayer AG
13.5. Boehringer Ingelheim International GmbH
13.6. Bristol-Myers Squibb Company
13.7. Cipla Inc.
13.8. Dr. Reddys Laboratories Ltd.
13.9. Eli Lilly and Company
13.10. F. Hoffmann-La Roche AG
13.11. GlaxoSmithKline PLC
13.12. Johnson & Johnson
13.13. Merck & Co. Inc.
13.14. Mindray Medical International Limited
13.15. Novartis AG
13.16. Novo Nordisk A/S
13.17. Pfizer Inc.
13.18. Shionogi & Co., Ltd.
13.19. Siemens Healthcare AG
13.20. Sun Pharmaceutical Industries Limited
13.21. Sysmex Corporation
13.22. Teva Pharmaceutical Industries Ltd.
13.23. Urit Medical Electronic Co., Ltd.
13.24. Viatris Inc.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL URINARY TRACT INFECTION MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET DYNAMICS
FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2022 VS 2030 (%)
FIGURE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 14. GLOBAL URINARY TRACT INFECTION MARKET COMPETITIVE STRATEGIC WINDOW, BY CLINICAL INDICATION, 2030
FIGURE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, 2018-2030 (USD BILLION)
FIGURE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, 2018-2030 (USD BILLION)
FIGURE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, 2018-2030 (USD BILLION)
FIGURE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 20. GLOBAL URINARY TRACT INFECTION MARKET COMPETITIVE STRATEGIC WINDOW, BY TREATMENT, 2030
FIGURE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD BILLION)
FIGURE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD BILLION)
FIGURE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD BILLION)
FIGURE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, 2018-2030 (USD BILLION)
FIGURE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, 2018-2030 (USD BILLION)
FIGURE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY Β-LACTAM, 2018-2030 (USD BILLION)
FIGURE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 29. GLOBAL URINARY TRACT INFECTION MARKET COMPETITIVE STRATEGIC WINDOW, BY END USER, 2030
FIGURE 30. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD BILLION)
FIGURE 31. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, 2018-2030 (USD BILLION)
FIGURE 32. AMERICAS URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 33. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 34. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 35. AMERICAS URINARY TRACT INFECTION MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 36. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 37. BRAZIL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 38. CANADA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 39. MEXICO URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 40. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 41. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 42. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 43. UNITED STATES URINARY TRACT INFECTION MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 44. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 45. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 46. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 47. ASIA-PACIFIC URINARY TRACT INFECTION MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 48. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 49. CHINA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 50. INDIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 51. INDONESIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 52. JAPAN URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 53. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 54. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 55. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 56. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 57. TAIWAN URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 58. THAILAND URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 59. VIETNAM URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 64. DENMARK URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 65. EGYPT URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 66. FINLAND URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 67. FRANCE URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 68. GERMANY URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 69. ISRAEL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 70. ITALY URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 71. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 72. NIGERIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 73. NORWAY URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 74. POLAND URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 75. QATAR URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 76. RUSSIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 77. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 78. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 79. SPAIN URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 80. SWEDEN URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 81. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 82. TURKEY URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 83. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 84. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 85. GLOBAL URINARY TRACT INFECTION MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 86. GLOBAL URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 87. GLOBAL URINARY TRACT INFECTION MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL URINARY TRACT INFECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2030 (USD BILLION)
TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, 2018-2030 (USD BILLION)
TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2030 (USD BILLION)
TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2030 (USD BILLION)
TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, 2018-2030 (USD BILLION)
TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2018-2030 (USD BILLION)
TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2018-2030 (USD BILLION)
TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, 2018-2030 (USD BILLION)
TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY REGION, 2018-2030 (USD BILLION)
TABLE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY REGION, 2018-2030 (USD BILLION)
TABLE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD BILLION)
TABLE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD BILLION)
TABLE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD BILLION)
TABLE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD BILLION)
TABLE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, BY REGION, 2018-2030 (USD BILLION)
TABLE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, BY REGION, 2018-2030 (USD BILLION)
TABLE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD BILLION)
TABLE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD BILLION)
TABLE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD BILLION)
TABLE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, 2018-2030 (USD BILLION)
TABLE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD BILLION)
TABLE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD BILLION)
TABLE 29. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, 2018-2030 (USD BILLION)
TABLE 30. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD BILLION)
TABLE 31. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD BILLION)
TABLE 32. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY Β-LACTAM, 2018-2030 (USD BILLION)
TABLE 33. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY Β-LACTAM, BY REGION, 2018-2030 (USD BILLION)
TABLE 34. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY Β-LACTAM, BY REGION, 2018-2030 (USD BILLION)
TABLE 35. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 36. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD BILLION)
TABLE 37. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD BILLION)
TABLE 38. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD BILLION)
TABLE 39. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, 2018-2030 (USD BILLION)
TABLE 40. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2030 (USD BILLION)
TABLE 41. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2030 (USD BILLION)
TABLE 42. AMERICAS URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 43. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 44. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 45. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 46. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 47. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 48. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 49. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 50. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 51. BRAZIL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 52. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 53. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 54. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 55. CANADA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 56. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 57. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 58. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 59. MEXICO URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 60. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 61. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 62. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 63. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 64. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2018-2030 (USD BILLION)
TABLE 65. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 66. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 67. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 68. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 69. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 70. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 71. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 72. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 73. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 74. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 75. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 76. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 77. CHINA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 78. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 79. CHINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 80. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 81. INDIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 82. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 83. INDIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 84. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 85. INDONESIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 86. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 87. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 88. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 89. JAPAN URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 90. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 91. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 92. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 93. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 94. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 95. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 96. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 97. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 98. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 99. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 100. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 101. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 102. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 103. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 104. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 105. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 106. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 107. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 108. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 109. TAIWAN URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 110. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 111. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 112. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 113. THAILAND URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 114. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 115. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 116. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 117. VIETNAM URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 118. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 119. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 120. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 126. DENMARK URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 127. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 128. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 129. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 130. EGYPT URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 131. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 132. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 133. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 134. FINLAND URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 135. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 136. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 137. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 138. FRANCE URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 139. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 140. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 141. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 142. GERMANY URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 143. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 144. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 145. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 146. ISRAEL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 147. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 148. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 149. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 150. ITALY URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 151. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 152. ITALY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 153. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 154. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 155. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 156. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 157. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 158. NIGERIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 159. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 160. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 161. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 162. NORWAY URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 163. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 164. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 165. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 166. POLAND URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 167. POLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 168. POLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 169. POLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 170. QATAR URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 171. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 172. QATAR URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 173. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 174. RUSSIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 175. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 176. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 177. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 178. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 179. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 180. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 181. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 182. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 183. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 184. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 185. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 186. SPAIN URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 187. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 188. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 189. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 190. SWEDEN URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 191. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 192. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 193. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 194. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 195. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 196. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 197. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 198. TURKEY URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 199. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 200. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 201. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 202. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 203. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 204. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 205. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 206. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 207. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD BILLION)
TABLE 208. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 209. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 210. GLOBAL URINARY TRACT INFECTION MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 211. GLOBAL URINARY TRACT INFECTION MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 212. GLOBAL URINARY TRACT INFECTION MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 213. GLOBAL URINARY TRACT INFECTION MARKET RANKING, BY KEY PLAYER, 2022
TABLE 214. GLOBAL URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2022
TABLE 215. GLOBAL URINARY TRACT INFECTION MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 216. GLOBAL URINARY TRACT INFECTION MARKET MERGER & ACQUISITION
TABLE 217. GLOBAL URINARY TRACT INFECTION MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 218. GLOBAL URINARY TRACT INFECTION MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 219. GLOBAL URINARY TRACT INFECTION MARKET INVESTMENT & FUNDING
TABLE 220. GLOBAL URINARY TRACT INFECTION MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 221. GLOBAL URINARY TRACT INFECTION MARKET: LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Almirall, S.A.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddys Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mindray Medical International Limited
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Siemens Healthcare AG
  • Sun Pharmaceutical Industries Limited
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Urit Medical Electronic Co., Ltd.
  • Viatris Inc.

Methodology

Loading
LOADING...